The proposed developmental funds constitute an invaluable flexible funding source for the UCCC to pursue the initiatives and research opportunities identified though the planning and evaluation activities of the Cancer Center. The UCCC proposes to use these funds to 1) strengthen scientific programs, 2) support faculty recruitment in areas of strategic focus and need, 3) provide both junior and more established investigators the opportunity to explore research ideas of particular innovation and collaboration through pilot grant program funds, and 4) support the development of two new shared resources. Specifically, the UCCC proposes to allocate $200K per year in support of recruitment for seven faculty: Associate Director for Basic Science;senior breast and prostate cancer investigator;senior bladder cancer biologist;senior metastasis investigator and senior immunologist for the developing Metastasis and Tumor Microenvironment Program;and Program Co-leader for Cancer Cell Biology. An annual budget of $200K is proposed in support of the broad-based and diverse UCCC Pilot Grant Programs. A budget of $100K is proposed for each of two developing shared resources: 1) Preclinical Animal Services SR and 2) Human Research Imaging. Funding for these proposed projects totals $600K per year. For all categories of the request, the proposed funds will be supplemented to significant degrees by other institutional sources of funds. In summary, these funds provide a means to pursue the particulariy new and innovative initiatives, not generally funded by established sponsored research entities that potentiate Center-defining areas of scientific research.

Public Health Relevance

An NCl-designated Comprehensive Cancer Center, the UCCC is dedicated to the discovery of the nature of cancer and the development of more effective approaches to prevention, diagnosis and therapy. The requested Developmental funds provide flexibility to recruit faculty, fund pilot grants, and develop shared resources that strengthen the UCCC's research programs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA046934-26
Application #
8616646
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-02-01
Budget End
2015-01-31
Support Year
26
Fiscal Year
2014
Total Cost
$458,345
Indirect Cost
$155,376
Name
University of Colorado Denver
Department
Type
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Villalobos, Victor Manuel; Hall, Francis; Jimeno, Antonio et al. (2018) Long-Term Follow-Up of Desmoid Fibromatosis Treated with PF-03084014, an Oral Gamma Secretase Inhibitor. Ann Surg Oncol 25:768-775
Montford, John R; Lehman, Allison M B; Bauer, Colin D et al. (2018) Bone marrow-derived cPLA2? contributes to renal fibrosis progression. J Lipid Res 59:380-390
Kogut, Igor; McCarthy, Sandra M; Pavlova, Maryna et al. (2018) High-efficiency RNA-based reprogramming of human primary fibroblasts. Nat Commun 9:745
Collins, Keagan P; Jackson, Kristen M; Gustafson, Daniel L (2018) Hydroxychloroquine: A Physiologically-Based Pharmacokinetic Model in the Context of Cancer-Related Autophagy Modulation. J Pharmacol Exp Ther 365:447-459
Goodspeed, Andrew; Jean, Annie; Costello, James C (2018) A Whole-genome CRISPR Screen Identifies a Role of MSH2 in Cisplatin-mediated Cell Death in Muscle-invasive Bladder Cancer. Eur Urol :
Niemeyer, Brian F; Oko, Lauren M; Medina, Eva M et al. (2018) Host Tumor Suppressor p18INK4c Functions as a Potent Cell-Intrinsic Inhibitor of Murine Gammaherpesvirus 68 Reactivation and Pathogenesis. J Virol 92:
Kiseljak-Vassiliades, Katja; Zhang, Yu; Bagby, Stacey M et al. (2018) Development of new preclinical models to advance adrenocortical carcinoma research. Endocr Relat Cancer 25:437-451
Nellan, Anandani; Rota, Christopher; Majzner, Robbie et al. (2018) Durable regression of Medulloblastoma after regional and intravenous delivery of anti-HER2 chimeric antigen receptor T cells. J Immunother Cancer 6:30
Abraham, Christopher G; Ludwig, Michael P; Andrysik, Zdenek et al. (2018) ?Np63? Suppresses TGFB2 Expression and RHOA Activity to Drive Cell Proliferation in Squamous Cell Carcinomas. Cell Rep 24:3224-3236
Sanchez, Gilson J; Richmond, Phillip A; Bunker, Eric N et al. (2018) Genome-wide dose-dependent inhibition of histone deacetylases studies reveal their roles in enhancer remodeling and suppression of oncogenic super-enhancers. Nucleic Acids Res 46:1756-1776

Showing the most recent 10 out of 1634 publications